SLEDAI-2K
Assess disease activity in lupus
The SLEDAI was originally developed to determine disease activity in patients with lupus.
SLEDAI-2K was developed as a modification of SLEDAI in order to include persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences. Specifically SLEDAI-2K allows persistent active disease in alopecia, mucous membrane ulcers, rash, and proteinuria to be scored.
SLEDAI-2K was validated against the original SLEDAI as a predictor for mortality and as a measure of global disease activity. It was also found to be equivalent to SLEDAI in describing changes in disease activity from one visit to the next.
- [1]Gladman DD, Ibañez D, Urowitz MB.: Systemic lupus erythematosus disease activity index 2000.Journal of Rheumatology 2002, 29 (2): 288-91
- [2]Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.: The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.
Results
Real-time automated computation
The SLEDAI was originally developed to determine disease activity in patients with lupus.
SLEDAI-2K was developed as a modification of SLEDAI in order to include persistent, active disease in those descriptors that had previously only considered new or recurrent occurrences. Specifically SLEDAI-2K allows persistent active disease in alopecia, mucous membrane ulcers, rash, and proteinuria to be scored.
SLEDAI-2K was validated against the original SLEDAI as a predictor for mortality and as a measure of global disease activity. It was also found to be equivalent to SLEDAI in describing changes in disease activity from one visit to the next.
- [1]Gladman DD, Ibañez D, Urowitz MB.: Systemic lupus erythematosus disease activity index 2000.Journal of Rheumatology 2002, 29 (2): 288-91
- [2]Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE.: The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.